Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genscript Biotech ( (HK:1548) ) just unveiled an update.
Genscript Biotech Corporation announced the financial results for the third quarter of 2025 for its associate, Legend Biotech Corporation, which is listed on the Nasdaq Global Select Market. The announcement highlights that these results pertain solely to Legend Biotech, and investors are advised to exercise caution when dealing with Genscript’s securities, indicating a focus on transparency and risk management.
The most recent analyst rating on (HK:1548) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a company incorporated in the Cayman Islands, operating in the biotechnology industry. It is involved in various biotech services and products, with a focus on innovative solutions and market expansion.
Average Trading Volume: 14,011,513
Technical Sentiment Signal: Buy
Current Market Cap: HK$35.14B
Find detailed analytics on 1548 stock on TipRanks’ Stock Analysis page.